Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker.

Jan M, Chao MP, Cha AC, Alizadeh AA, Gentles AJ, Weissman IL, Majeti R.

Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):5009-14. doi: 10.1073/pnas.1100551108. Epub 2011 Mar 7.

2.

The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients.

Hoang VT, Buss EC, Wang W, Hoffmann I, Raffel S, Zepeda-Moreno A, Baran N, Wuchter P, Eckstein V, Trumpp A, Jauch A, Ho AD, Lutz C.

Int J Cancer. 2015 Aug 1;137(3):525-36. doi: 10.1002/ijc.29410. Epub 2015 Jan 14.

3.

Normal hematopoietic stem cells within the AML bone marrow have a distinct and higher ALDH activity level than co-existing leukemic stem cells.

Schuurhuis GJ, Meel MH, Wouters F, Min LA, Terwijn M, de Jonge NA, Kelder A, Snel AN, Zweegman S, Ossenkoppele GJ, Smit L.

PLoS One. 2013 Nov 11;8(11):e78897. doi: 10.1371/journal.pone.0078897. eCollection 2013.

4.

TIM3 expression by leukemic and non-leukemic myeloblasts.

Roth CG, Garner K, Eyck ST, Boyiadzis M, Kane LP, Craig FE.

Cytometry B Clin Cytom. 2013 May;84(3):167-72. doi: 10.1002/cyto.b.21080. Epub 2013 Mar 29.

5.

Identification and separation of normal hematopoietic stem cells and leukemia stem cells from patients with acute myeloid leukemia.

Hoang VT, Hoffmann I, Borowski K, Zepeda-Moreno A, Ran D, Buss EC, Wuchter P, Eckstein V, Ho AD.

Methods Mol Biol. 2013;1035:217-30. doi: 10.1007/978-1-62703-508-8_19.

PMID:
23959995
6.

Identification of leukemia stem cells in acute myeloid leukemia and their clinical relevance.

Hoang VT, Zepeda-Moreno A, Ho AD.

Biotechnol J. 2012 Jun;7(6):779-88. doi: 10.1002/biot.201100350. Epub 2012 May 16. Review.

PMID:
22588704
7.

Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells.

Moore MA, Dorn DC, Schuringa JJ, Chung KY, Morrone G.

Exp Hematol. 2007 Apr;35(4 Suppl 1):105-16.

PMID:
17379095
8.

Leukemic progenitor cells are susceptible to targeting by stimulated cytotoxic T cells against immunogenic leukemia-associated antigens.

Schneider V, Zhang L, Rojewski M, Fekete N, Schrezenmeier H, Erle A, Bullinger L, Hofmann S, Götz M, Döhner K, Ihme S, Döhner H, Buske C, Feuring-Buske M, Greiner J.

Int J Cancer. 2015 Nov 1;137(9):2083-92. doi: 10.1002/ijc.29583. Epub 2015 May 13.

9.

Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells.

Gal H, Amariglio N, Trakhtenbrot L, Jacob-Hirsh J, Margalit O, Avigdor A, Nagler A, Tavor S, Ein-Dor L, Lapidot T, Domany E, Rechavi G, Givol D.

Leukemia. 2006 Dec;20(12):2147-54. Epub 2006 Oct 12.

PMID:
17039238
10.

Study of morphocytochemical and immunophenotypic features of acute leukemia stem cells.

Gluzman DF, Nadgornaya VA, Sklyarenko LM, Zavelevych MP, Koval SV, Poludnenko LY, Ivanovskaya TS.

Exp Oncol. 2008 Jun;30(2):102-5. Review.

PMID:
18566571
11.

CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia.

Hosen N, Park CY, Tatsumi N, Oji Y, Sugiyama H, Gramatzki M, Krensky AM, Weissman IL.

Proc Natl Acad Sci U S A. 2007 Jun 26;104(26):11008-13. Epub 2007 Jun 18.

12.

TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells.

Kikushige Y, Shima T, Takayanagi S, Urata S, Miyamoto T, Iwasaki H, Takenaka K, Teshima T, Tanaka T, Inagaki Y, Akashi K.

Cell Stem Cell. 2010 Dec 3;7(6):708-17. doi: 10.1016/j.stem.2010.11.014.

13.

Differential niche and Wnt requirements during acute myeloid leukemia progression.

Lane SW, Wang YJ, Lo Celso C, Ragu C, Bullinger L, Sykes SM, Ferraro F, Shterental S, Lin CP, Gilliland DG, Scadden DT, Armstrong SA, Williams DA.

Blood. 2011 Sep 8;118(10):2849-56. doi: 10.1182/blood-2011-03-345165. Epub 2011 Jul 15.

14.

Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia.

Terwijn M, Zeijlemaker W, Kelder A, Rutten AP, Snel AN, Scholten WJ, Pabst T, Verhoef G, Löwenberg B, Zweegman S, Ossenkoppele GJ, Schuurhuis GJ.

PLoS One. 2014 Sep 22;9(9):e107587. doi: 10.1371/journal.pone.0107587. eCollection 2014.

15.

p27kip1 maintains a subset of leukemia stem cells in the quiescent state in murine MLL-leukemia.

Zhang J, Seet CS, Sun C, Li J, You D, Volk A, Breslin P, Li X, Wei W, Qian Z, Zeleznik-Le NJ, Zhang Z, Zhang J.

Mol Oncol. 2013 Dec;7(6):1069-82. doi: 10.1016/j.molonc.2013.07.011. Epub 2013 Aug 20.

16.

CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice.

Tavor S, Petit I, Porozov S, Avigdor A, Dar A, Leider-Trejo L, Shemtov N, Deutsch V, Naparstek E, Nagler A, Lapidot T.

Cancer Res. 2004 Apr 15;64(8):2817-24.

17.

[A TIM-3/galectin-9 autocrine stimulatory loop drives self-renewal of human myeloid leukemia stem cells and leukemia progression].

Kikushige Y.

Rinsho Ketsueki. 2016 Apr;57(4):412-6. doi: 10.11406/rinketsu.57.412. Japanese.

PMID:
27169443
18.
19.

Identification of TIM-3 as a Leukemic Stem Cell Surface Molecule in Primary Acute Myeloid Leukemia.

Kikushige Y, Miyamoto T.

Oncology. 2015;89 Suppl 1:28-32. doi: 10.1159/000431062. Epub 2015 Nov 10. Review.

PMID:
26551150
20.

MicroSPECT/CT imaging of primary human AML engrafted into the bone marrow and spleen of NOD/SCID mice using 111In-DTPA-NLS-CSL360 radioimmunoconjugates recognizing the CD123+ / CD131- epitope expressed by leukemia stem cells.

Leyton JV, Williams B, Gao C, Keating A, Minden M, Reilly RM.

Leuk Res. 2014 Nov;38(11):1367-73. doi: 10.1016/j.leukres.2014.09.005. Epub 2014 Sep 20.

PMID:
25278187

Supplemental Content

Support Center